Overall, findings of loss of muscarinic receptors in the brain tissue in autism and FXS and the observed beneficial action of cholinomimetics and Ache inhibitors represent a relevant step forward the development of novel targeted pharmacological treatments for AD, FXS and ASD related disorders. The gene discussed is ACHE; the disease is fragile X syndrome.